SARS CoV 2 News and Research

RSS

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

A possible protective genetic polymorphism in COVID-19

A new study discusses the role of a mucin gene enhancer on the clinical phenotype of the COVID-19.

5 Oct 2021

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.

5 Oct 2021

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

Emergence and evolution of endemic and emerging coronavirus diversity in humans and animals

A study aimed to understand the evolutionary and epidemiology dynamics of coronavirus diversity in animals, humans, and wildlife at ecosystem interfaces.

5 Oct 2021

Connection between aerosol transmission and COVID-19 dynamics

A simulation study explored event-level overdispersion of SARS-Cov-2 spread, utilizing real-world inputs from a large number of social gatherings.

5 Oct 2021

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3’s scaffolding ability, independent of cell death.

5 Oct 2021

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

A new systematic review and meta-analysis focused on the humoral and cell-mediated immune responses after COVID-19 vaccination in patients undergoing anti-CD20 antibodies treatment.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study suggests shingles vaccine reduces the risk for COVID-19

People who get the shingles vaccine may have a lower risk of being diagnosed and hospitalized with coronavirus disease 2019 (COVID-19), according to a new medRxiv* preprint study. In about 150,000 people over the age of 50, vaccination for shingles was associated with a 32% reduced risk of severe COVID-19 infection.

5 Oct 2021

New study underscores the importance of improving COVID-19 vaccination rates worldwide

Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from Kaiser Permanente and Pfizer published in The Lancet.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

What makes SARS-CoV-2 variants more virulent?

Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest.

4 Oct 2021

Scientists analyze if T-cell tests can be used to determine whether people had COVID-19

Can T-cell tests be used to determine whether people have had COVID-19? Scientists at Uppsala University and Karolinska Institutet have jointly analysed this issue under the aegis of the COMMUNITY study at Danderyd Hospital. Their study is published in the scientific journal PLOS ONE.

4 Oct 2021

Fully vaccinated people with prior SARS-CoV-2 infection have more memory B cells, study shows

A new study by University of Minnesota Medical School researchers is revealing that some people who received an mRNA vaccination for COVID-19 have greater immune responses compared to others.

4 Oct 2021

Moderna's COVID-19 vaccine proves effective against multiple SARS-CoV-2 variants, including delta

Researchers in the United States have demonstrated the real-world effectiveness of Moderna’s mRNA-1273 vaccine at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and preventing hospitalization due to coronavirus disease 2019 (COVID-19).

4 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

Specific wavelength of UV light is safe and effective way to kill SARS-CoV-2 virus

A specific wavelength of ultraviolet (UV) light is not only extremely effective at killing the virus which causes COVID-19, but is also safer for use in public spaces, finds new University of Colorado Boulder research.

4 Oct 2021

SARS CoV 2 News and Research

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A possible protective genetic polymorphism in COVID-19

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

Emergence and evolution of endemic and emerging coronavirus diversity in humans and animals

Connection between aerosol transmission and COVID-19 dynamics

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Study suggests shingles vaccine reduces the risk for COVID-19

New study underscores the importance of improving COVID-19 vaccination rates worldwide

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

What makes SARS-CoV-2 variants more virulent?

Scientists analyze if T-cell tests can be used to determine whether people had COVID-19

Fully vaccinated people with prior SARS-CoV-2 infection have more memory B cells, study shows

Moderna's COVID-19 vaccine proves effective against multiple SARS-CoV-2 variants, including delta

Study looks at immunosuppressants and COVID vaccine efficacy

Specific wavelength of UV light is safe and effective way to kill SARS-CoV-2 virus

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News